MPIIBMax Planck Institute for Infection Biology
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
QIAGEN N.V (Nasdaq:QGEN (XETRA: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology today announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.
QIAGEN will be responsible for assay design and manufacturing, while MPIIB will offer access to its marker sets and develop new biosignatures.